Cannabis dependence in the San Francisco Family Study: Age of onset of use, DSM-IV symptoms, withdrawal, and heritability by Ehlers, Cindy L. et al.
Cannabis dependence in the San Francisco Family Study: age of
onset of use, DSM-IV symptoms, withdrawal, and heritability
Cindy L. Ehlersb, Ian R. Gizera, Cassandra Vietenc, David A. Gilderb, Gina M. Stoufferb, Philip
Laub, and Kirk C. Wilhelmsena
aDepartment of Neurology and Genetics and the Bowles Center for Alcohol Studies, University of
North Carolina, 4109 Neurosciences Research Bldg, CB#7264, Chapel Hill, NC 27599, USA
bDepartment of Molecular and Integrative Neurosciences, The Scripps Research Institute, 10550
North Torrey Pines Road, SP30-1501, La Jolla, CA 92037, USA
cCalifornia Pacific Medical Center Research Institute, 2200 Webster Street, Rm. 514, San
Francisco, CA 94115, USA.
Abstract
Cannabis is the most widely used illicit drug in the United States, yet the role of genetics in individual
symptoms associated with cannabis use disorders has not been evaluated. The purpose of the present
set of analyses was to describe the symptomatology and estimate the heritability of DSM-IV criteria/
symptoms of cannabis dependence in a large sample of families. Participants were 2524 adults,
participating in the University of California San Francisco (UCSF) Family Study of alcoholism.
Seventy percent of the sample had ever used cannabis and 13.9% met DSM-IV criteria for cannabis
dependence. Younger age at first cannabis use was found to be significantly associated with a
shortened survival to becoming cannabis dependent. Although a greater percentage of men met
criteria for cannabis dependence, women were found to demonstrate “telescoping” as indexed by a
shorter survival time from initial use to dependence as compared to men. A cannabis withdrawal
syndrome was identified in users, the primary symptoms of which were nervousness, appetite change,
and sleep disturbance. Cannabis use (h2 = 0.31) and dependence (h2 = 0.20), age at first use, individual
DSM-IV criteria for dependence, and cannabis-use associated symptoms of depression, trouble
concentrating and paranoia were all found to be heritable. These findings suggest that within this
population that cannabis use and dependence, as well as individual cannabis dependence symptoms
have a significant heritable component, that cannabis dependence is more likely to occur when use
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begins during adolescence, and that the cannabis dependence syndrome includes a number of
heritable untoward psychiatric side effects including withdrawal.
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1. Introduction
1.1. Prevalence of cannabis use disorders and its association with physical and mental
health problems
National epidemiological samples have demonstrated that cannabis is the most commonly used
illicit drug (Anthony, Warner & Kessler, 1994; Stinson et al., 2005; Stinson, Ruan, Pickering
& Grant, 2006), and that its use has substantially increased over the last decade (Compton,
Grant, Colliver, Glantz & Stinson, 2004). The prevalence of dependence on cannabis in the
United States appears to be higher than any other illicit drug. The 2003 National Survey on
Drug Use and Health (Substance Abuse and Mental Health Services Administration
[SAMHSA], 2003) reported that 40.6% of the U.S. population had used cannabis or hashish
during their lifetime and that 4.2 million individuals age 12 years and older met criteria for
past year cannabis abuse or dependence using DSM-IV (American Psychiatric Association,
1994) criteria. Lifetime rates of cannabis dependence in the National Epidemiologic Survey
of Alcohol and Related Conditions (NESARC) were reported to be 1.3%, rates of 1.8% were
found in the National Longitudinal Alcohol Epidemiologic Study (NLAES) and 4.2 % in the
National Co-morbidity study (NCS) (see Anthony et al., 1994; Compton et al., 2004).
Chronic use of cannabis is associated with both physical and mental health problems. Persistent
use poses health problems similar to those of tobacco (Fisher, Ghuran, Vadamalai & Antonios,
2005; Hashibe et al., 2005; Mittleman, Lewis, Maclure, Sherwood & Muller, 2001; Tashkin,
2005; Taylor, Poulton, Moffitt, Ramankutty & Sears, 2000). Cannabis use has also been
implicated in a syndrome characterized by apathy, loss of goal-directed behavior, and cognitive
impairment termed the “amotivational syndrome” (Pope, Gruber, Hudson, Huestis &
Yurgelun-Todd, 2001; Schuckit, 2006; Sharma, 1975; Solowij et al., 2002). Cannabis use is
associated with psychotic illness and depression (Degenhardt, Hall & Lynskey, 2003; Hall,
Degenhardt & Teesson, 2004), as well as impaired educational and work performance (Kandel
& Chen, 2000; Lynskey & Hall, 2000; Schuckit, 2006; Swift, Hall & Teesson, 2001). Early
use of cannabis is associated with a higher likelihood of developing cannabis dependence
(Chen, Storr & Anthony, 2009; Ehlers, Slutske, Gilder, Lau & Wilhelmsen, 2006; Swift,
Coffey, Carlin, Degenhardt & Patton, 2008). Use of cannabis, particularly by adolescents and
young adults, may also facilitate progression to other illicit drug use (the “gateway” drug
hypothesis) (Behrendt, Wittchen, Höfler, Lieb & Beesdo, 2009; Degenhardt et al., 2009;
Fergusson & Horwood, 2000; Lynskey et al., 2003).
1.2. Genetic influences on cannabis use and use disorders
Twin and family studies have consistently found that cannabis use disorders appear to have a
genetic component (for review see Agrawal & Lynskey, 2006). Correlations between parents
and offspring and between siblings typically range from 0.3–0.6 (Bierut et al., 1998; Gfroerer,
1987; Hopfer, Stallings, Hewitt & Crowley, 2003; Meller, Rinehart, Cadoret & Troughton,
1988; Merikangas et al., 1998) for cannabis use. Twin studies of cannabis use have reported
heritability estimates that ranging from 0.17 to 0.67, whereas studies that have evaluated the
role of genetic and environmental risk factors on cannabis abuse or cannabis dependence in
twin samples have found significantly higher estimates of heritability (estimates range from
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0.45 to 0.78) (see Kendler & Prescott, 1998; Kendler, Karkowski, Neale & Prescott, 2000;
Maes et al., 1999; McGue, Elkins & Iacona, 2000; Miles et al., 2001; Rhee et al., 2003; Tsuang
et al., 1998; van den Bree et al., 1998).
DSM-IV requires that three out of six groups of symptoms must be present to make a diagnosis
of cannabis dependence (American Psychiatric Association, 1994), so theoretically a number
of different symptom combinations could lead to a diagnosis. Evaluation of data from the
NESARC suggests that cannabis dependence appears to be a highly heterogeneous disorder
and does present in a diverse set of symptom combinations (Blanco et al., 2008). One
interpretation of these findings is that cannabis use directly and independently affects a variety
of behaviors indexed by the dependence criteria but that individual vulnerability may influence
which symptoms are actually expressed. If this theory is correct, then it may be further posited
that different symptoms or clusters of symptoms may have a unique genetic or environmental
basis. For instance, a number of studies have reported that cannabis “craving” is one of the
most common symptoms reported during withdrawal and that it significantly contributes to
failed quit attempts (see Budney, Novy & Hughes, 1999; Budney, Vandry, Hughes, Thostenson
& Bursac, 2008; Cornelius, Chung, Martin, Wood & Clark, 2008; Heishman et al., 2009;
McRae, Hedden, Malcolm, Carter & Brady, 2007) Recent data suggest that a history of parental
alcohol/drug problems is associated with an increased likelihood of experiencing cannabis
withdrawal, suggesting that it may in part be heritable (Agrawal et al., 2008a). While the clinical
symptomatology of cannabis use and cannabis dependence have been previously described in
large nationwide epidemiological studies and cannabis dependence has been shown to be
heritable, to date, genetic analyses of individual DSM-IV cannabis dependence criteria/
symptoms and cannabis induced symptomatolgy, such as withdrawal and craving, has not been
published.
1.3. The present study
The goals of the present study were to describe the prevalence of a number of clinical symptoms
associated with use of cannabis in this population in men and women and to estimate the
heritability of: cannabis use, cannabis dependence, as well as the individual DSM-IV criteria
and other symptoms associated with cannabis dependence using the University of California
San Francisco (UCSF) Family Study of alcoholism dataset. Specifically the prevalence of
cannabis use and its transition to dependence, the prevalence of each of the DSM-IV cannabis
dependence criteria and cannabis-induced psychiatric symptoms, such as craving, depression,
trouble concentrating, psychotic symptoms as well as the extent to which cannabis users
experiences symptoms of withdrawal and seek treatment was evaluated. The heritability of
cannabis use, DSM-IV cannabis dependence and individual criteria/symptoms of cannabis
dependence and cannabis-induced symptomatology was also estimated.
The UCSF Family Alcoholism Study is a project that was designed to identify genetic loci that
influence susceptibility to alcohol dependence and related phenotypes. It used a small family
design, focusing primarily on sibling pairs and parent-child trios. The study enrolled 2454
individuals from 970 families from December 1995 through January 2003. Test-retest and
inter-rater reliability for clinical data have been shown to be very good. Design, methods, and
sample demographics of the UCSF Family Alcoholism Study have been presented previously
(see Seaton, Cornell, Wilhelmsen & Vieten, 2004; Vieten, Seaton, Feiler & Wilhelmsen,
2004), along with intrafamilial correlations for primary diagnostic phenotypes.
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2.1. Participants and recruitment
The UCSF Family Study is a behavioral genetics study that recruited probands with alcohol
dependence and the relatives of those probands, nationwide. In addition, a community sample
was ascertained in order to estimate population means and standard deviations for heritability
and linkage analyses. Participants were recruited through the use of semi-targeted direct mail,
a web site, press releases, and advertisements, and from alumni of treatment centers across the
nation. Thirty-three percent of the probands were recruited from the general population random
mailings, 32% from community organizations, 18% from treatment program alumni, and 17
% from other sources. Probands reporting serious drug dependence (defined as use of
stimulants, cocaine, or opiates daily for more than 3 months or weekly for more than 6 months),
current or past diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness
involving psychotic symptoms, a life-threatening illness, or an inability to speak and read
English were excluded. The details of recruitment of all participants have been previously
published (see Seaton et al., 2004; Veiten et al., 2004)
2.2. Measures of assessment
A remote data collection procedure was developed allowing for blood samples for genotyping
and other questionnaires to be returned by mail, and structured diagnostic interviews to be
conducted by telephone, making nationwide data collection possible. Potential participants
first had the study explained and gave written informed consent. A modified version of the
Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz, et al.,
1994) was used to collect demographic, medical, psychiatric, alcohol, nicotine, and other drug
use history. The SSAGA is a fully structured, poly-diagnostic psychiatric interview that has
undergone both reliability and validity testing. Modifications of the SSAGA for the UCSF
study included changes in diagnostic criteria and items to obtain DSM-IV criteria. Only the
sections of the SSAGA relevant to substance abuse, demographics and medical history were
utilized. The SSAGA uses a criterion of having used cannabis 21 times in a single year as a
cut off for assessing the full range of use, abuse and dependence symptoms. Twenty percent
of those enrolled did not complete all study requirements. Only limited data were available for
non-completers, but follow-up analyses suggested that participants failing to complete the
study were more likely to be male (chi-square = 5.18, p=.025), and to use marijuana (chi-square
= 27.06, p<.001) Details of the interview process and inter-rater reliability of the SSAGA, and
complete demographic information in this study have been reported previously (Vieten et al.,
2004).
2.3. Statistical data analyses and estimates of heritability
The data analyses were based on the specific aims, the first aim of which was to describe the
full range of clinical symptomatology associated with cannabis use and dependence in the
UCSF Family Study population in men and women. These analyses allowed us to compare
clinical data to other large epidemiological samples drawn from a general population sample
as well as to identify variables that were present to a large enough extent in this population to
be suitable for heritability analyses. The first set of analyses evaluated the prevalence of, and
transitions from use to dependence in men and women in this sample. To accomplish these
analyses the transitions between the number of participants that endorsed: having ever tried
cannabis, having used at least 21 times in a single year (a cut off for estimating cannabis
symptomatology using the SSAGA), and having three DSM-IV symptom groups of
dependence were tallied and potential gender differences in these variables were calculated,
using chi-square. The conditional probabilities of the transitions from use to used 21 times and
from used 21 times to dependence were also estimated. This was accomplished by: (1) dividing
the number of participants who had used 21 times by the number of participants who had used,
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and (2) dividing the number of participants who had developed dependence by the number of
participants who had used 21 times, using the method described in Tsuang et al., (1999).
Potential gender differences in the conditional probabilities of transition were calculated using
the test statistic for two proportions. The co-morbidity of cannabis dependence with alcohol
dependence was also estimated.
The second set of analyses on the clinical dataset were conducted in order to determine whether
a significant association exists between age at first use and the presence of cannabis dependence
in this population, as has been seen in other populations. To test this hypothesis, the trajectory
between age of onset of first cannabis use and transition to cannabis dependence was
determined using survival analyses. The Kaplan-Meier method was used to estimate survival
time using a time to event model (time interval from first use to dependence) in the presence
of censored cases. Therefore, the age of onset of first use was used as the initial variable to:
(1) determine its association with cannabis dependence, and (2) to estimate the duration of time
elapsed between first use and the onset of dependence in the survival analyses.
The third set of analyses of the clinical dataset were conducted to determine the prevalence of
each of the DSM-IV cannabis dependence criteria/symptoms as well as other cannabis-induced
psychiatric symptoms, the extent to which cannabis users experiences symptoms of
withdrawal, and the types of treatment options participants had sought. To accomplish these
analyses the data were tallied and potential gender differences in these variables calculated
using chi-square.
The second overall aim of the study was to determine the heritability of cannabis use, DSM-
IV cannabis dependence and the individual criteria/symptoms of dependence as well as
“craving” (defined as: “in situations where you couldn’t use marijuana, did you ever have such
a strong desire for it that you couldn’t think of anything else?”), and cannabis withdrawal using
a family genetics design. Two thousand five hundred and twenty-two individuals from 890
pedigrees were included in the heritability analyses. The proportion of phenotypic variation
that is genetic assuming a simple additive model was estimated for the traits. The total additive
genetic heritability (h2) that represents the proportion of variation in the phenotype that is due
to genetic influences, and its standard error, were estimated using SOLAR v 2.0.4 (Almasy &
Blangero, 1998; Southwest Foundation of Biomedical Research [S.F.B.R], 2009). SOLAR
estimates heritability by partitioning the trait relative pair covariance into additive genetic and
environmental contributions. It should be noted that SOLAR relies on the inclusion of relative
pairs living apart to disentangle genetic and shared environmental influences. The UCSF
Family Study sample consists of 563 parent-child, 1085 sibling, 40 half sibling, 17 grandparent-
grandchild, 238 avuncular, and 32 cousin relative pairs that are genetically informative. This
combination of small and extended pedigrees provides some protection against the conflation
of additive genetic and shared environmental influences. Nonetheless, it should be noted that
without the inclusion of monozygotic twin pairs, these two sources of variation cannot be
perfectly disentangled, and a positive bias in heritability estimates can occur.
For all heritability analyses, subject’s age at the time of evaluation and gender were included
as potential covariates and retained if they accounted for at least 5% of the total variance in
the phenotype. The dichotomous traits were modeled as quantitative rather than using the
liability threshold model for discrete traits. It has been documented that this approach yields
more conservative estimates of heritability, and thus, this approach was used to further ensure
that the reported heritability estimates for the analyzed phenotypes were not positively biased.
Because the current sample was selected for alcohol dependence, it was also necessary to
correct for potential ascertainment biases. Collecting a sample selected for a specific disorder
frequently reduces the observed variation in the selected trait due to the over-sampling of
individuals at the high end of the distribution. In quantitative genetic analyses, this reduced
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variation can result in negatively biased estimates of heritability necessitating the inclusion of
methods to correct for such ascertainment bias. One such method is to constrain the sample
mean of the trait of interest to that observed in the general population. Simulation analyses
using SOLAR have suggested that this approach can be used to correct for such ascertainment
bias (Blangero, unpublished data as cited in Cripe, Andelfinger, Martin, Shooner & Benson,
2004), and thus, the mean prevalence rate for the cannabis dependence diagnosis was
constrained to the prevalence rate found in the UCSF control sample (i.e., 0.071) to correct for
ascertainment bias when estimating h2 for this diagnosis. Similarly, the prevalence rates for
each of the cannabis dependence symptoms were estimated in this control sample and used to
correct for any ascertainment bias when estimating h2 for those symptoms. Further details
regarding these methods have been described previously (Ehlers, Wall, Betancourt & Gilder,
2004, Ehlers et al., 2006; Wilhelmsen & Ehlers, 2005).
3. Results
3.1. Demographics
The demographic characteristics of this population have been presented previously (see Vieten
et al., 2004). In brief, the UCSF family sample (n=2377) had a mean age of 48.4 ± 13.4 years,
a mean educational level of 14.4 ± 2.9 years, and an annual income of $57,356 ± $54,656.
Racial distribution was: 92% Caucasian, 3% each African American and Hispanic, and 1%
each Native American and Other. Fifty-four percent were married. The sample was ascertained
to collect families with alcohol dependence from the community. Probands in this study were
58% female, with 97% of probands meeting lifetime criteria for alcohol dependence, whereas,
38% of the relatives of probands were found to be alcohol dependent. The control sample
(n=147) had similar demographic characteristics to the Family Study sample with 92% being
Caucasian, 58% being female, a mean age of 51.2 years, a mean income of $48,947, and a
mean education level of 14.0 yrs and with 15% having a lifetime history of DSM-IV alcohol
dependence and 7% a lifetime history of cannabis dependence.
3.2. Prevalence of cannabis use and use disorders in the SF Family Study population
As seen in table 1, 70% (n=1764) of the SF Family Study population had “tried” cannabis at
least once in their life. There were an equivalent number of males and females in the population
that had reported using the drug. Approximately, forty-five percent (44.9%, n=818) of the
population has used cannabis greater than 21 times in a single year, and among those
participants using cannabis at that level or greater, significantly more were men than women
(chi square =25.98, df=1, p<0.0001). Approximately fourteen percent (13.9%, n=349) of the
study population had a lifetime diagnosis of DSM-IV cannabis dependence and within this
group significantly more were men (chi-square=20.04, df=1, p<0.0001). The conditional
probability of: (1) transitioning from reporting having used cannabis to having used at least 21
times in a single year; and (2) transitioning from reporting having used at least 21 times in a
single year to meeting criteria for cannabis dependence was calculated for the entire sample
and for men and women separately (see table 1). Men were significantly more likely than
women to transition from use to used 21 times (z= 5.29; p<0.000001), as well as to transition
from used 21 times to dependence (z=2.13; p<0.03). Lifetime diagnosis of DSM-IV cannabis
dependence was also found to be significantly co-morbid with a lifetime diagnosis of alcohol
dependence (chi-square = 117.6, df=1, p<0.00001).
3.3. Effect of age at first cannabis use on the development of cannabis dependence
The mean (± S.D.) age of first cannabis use was 19.92 (± 8.55), and the mean age of cannabis
dependence was 28.28 (± 9.32). There were no significant differences between men and women
on mean age of onset of first cannabis use as estimated by survival to first cannabis use (Mantel
Cox Chi-Square =0.017, df=1, p=NS). Survival analyses did, however, reveal that having a
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lifetime cannabis dependence diagnosis was significantly associated with the age at which a
person reported first trying the drug. Figure 1 graphically represents the survival curves for:
ages <13 vs. 13 or greater, <15 vs. 15 or greater, <17 vs. 17 or greater, <19 vs. 19 or greater,
<21 vs. 21 or greater and <25 vs. 25 or greater, which were generated using the Kaplan-Meier
method. These survival curves were compared at each of the ages using the log-rank test of
the null hypothesis of a single survival curve. Significant differences (p<0.001) were found
for each age as seen in table 2. The actual survival time from first use to meeting criteria for
DSM-IV cannabis dependence was also compared for each age as indicated above using t-tests
and significant differences (p<0.0001) were found for: <13 vs. 13 or greater, <15 vs. 15 or
greater, <17 vs. 17 or greater, <19 vs. 19 or greater. Having tried cannabis at 13 or younger
was found to be associated with a mean survival time to cannabis dependence of 27.2 ± 2.2
years as opposed to 43.1 ± 0.5 years for individuals who did not try the drug until after the age
of 25. Overall survival time for the population was also found to be significantly different based
on gender (t= −3.756; p<0.0001), with women demonstrating a shorter survival time (44.07 ±
0.6 yrs) than men (49.3 ± 1.3 yrs).
3.4. Clinical symptoms resulting from cannabis use in the UCSF Family Study
Table 3 gives the prevalence of each of the DSM-IV cannabis dependence criteria/symptoms
in the portion of the population that had endorsed having ever taken cannabis at least 21 times
in a single year. The most commonly endorsed cannabis dependence symptom found in this
group of individuals was “continued to use marijuana despite emotional or psychological
problems”. The second most common dependence symptom was: “great deal of time spent
obtaining, using, or recovering from marijuana”. The prevalence of only two symptoms
differed between men and women: (1) “great deal of time spent obtaining, using, or recovering
from marijuana” and (2) tolerance. Of those participants who had used cannabis more than 21
times in a single year, 16.6% (n=135) endorsed having experienced cannabis withdrawal and
16.0% (n=130) reported using cannabis to avoid withdrawal. There were no gender differences
in the number of participants that endorsed cannabis withdrawal. Of those participants who
had experienced withdrawal, as seen in table 4, the most common symptom of withdrawal
endorsed was feeling “nervous, tense, restless or irritable”. The second and third most common
symptoms of withdrawal were “appetite change or weight change” and “trouble sleeping”.
Participants in the study who had taken cannabis more than 21 times in a single year also
reported experiencing a number of other psychiatric symptoms associated with that use that
lasted more than 24 hours, as seen in table 4. Within the group of participants who had endorsed
using cannabis more than 21 times in a single year 29.1% (n=231) reported having experienced
depression or disinterest in things, 32.8% (n=261) had reported being paranoid or suspicious
of people and 17.9% (n=142) had experienced hallucinations for more than a 24 hour period.
Of those who had used cannabis more than 21 times in a single year 36.6% (n=292) reported
that they wanted to stop using the drug, and 21% (n=167) reported having actually tried to stop
using cannabis but could not. Within the group of participants who had endorsed using cannabis
more than 21 times 17.9% (n=142) reported ever bringing up any problems they might have
had with cannabis with any professional including a member of the clergy.
3.5. Heritability analyses of cannabis use, use disorders and cannabis symptomatology
Table 5 lists the findings of the heritability analyses. Having ever tried cannabis (h2 =0.52,
p<0.0001), having used it at least 21 times in a single year (h2 =0.31, p<0.0001), and DSM-
IV cannabis dependence (h2 =0.20, p<0.0001) were all found to be significantly heritable.
Additionally, age at first cannabis use was also found to be heritable (h2 =0.22, p<0.002). When
heritability was estimated for DSM-IV cannabis dependence criteria/symptoms, individually,
all the symptoms were found to be significantly heritable (h2 = 0.10–0.29, p<0.01). In addition,
several untoward symptoms that participants reported experiencing for more than 24 hours
Ehlers et al. Page 7













were also found to be significantly heritable such as: depression (h2 =0.16, p<0.001), trouble
concentrating (h2 =0.19, p<0.0001) and paranoia (h2 =0.11, p<0.007). Additionally, two of the
symptoms that had the highest heritability were cannabis craving (h2 =0.36, p<0.0001) and
nervousness during cannabis withdrawal (h2 =0.28, p<0.001)
4. Discussion
4.1. Clinical symptoms associated with cannabis use in the San Francisco Family Study:
differences between in men and women
Cannabis is the most widely used illicit substance in the United States and world-wide (Hall
& Degenhardt, 2007; Maxwell, 2008). The prevalence of lifetime DSM-IV cannabis
dependence in the UCSF Family Study was elevated (13.9%) compared to the general
population but was similar to what has been reported for other high risk samples such as the
Collaborative Study of the Genetics of Alcoholism (COGA) where 20% of the genotyped
sample was found to have a lifetime diagnosis of cannabis dependence (Agrawal et al.,
2006). Gender differences in cannabis use, abuse, and dependence are a consistent finding in
the literature (see Grant & Pickering, 1998; McCrady & Epstein, 1999; Stinson et al., 2006).
This was also found to be true in the UCSF Family Study where although equivalent numbers
of men and women in the UCSF Family Study reported having used cannabis a significantly
higher proportion of men endorsed having used it 21 times or more in a single year and more
men than women met DSM-IV criteria for cannabis dependence.
Although a number of studies have demonstrated that cannabis use and dependence are more
common in men fewer studies have evaluated gender differences in the probability of becoming
dependent once use has begun. In a comparison of 6 illicit drugs/classes of drugs (cannabis,
amphetamine, cocaine, sedatives, heroin, psychedelics), Tsuang et al. (1999) found, using data
from the Vietnam Era Twin Registry (VETR), that cannabis had the highest conditional
probability for the transition from exposure to use (0.57), from use to use more than five times
(0.44), and from use more than five times to regular use (0.70). The conditional probability of
transition from regular use of cannabis to cannabis use disorders was 0.33 in the VETR study.
However, the VETR study only evaluated male-male twins and thus information for female
users was not available. In the present study, conditional probabilities for transition from use
to used 21 times (0.46) and from used 21 times to dependence (0.43) were similar to the ranges
found in the VETR study; however, in the UCSF study we were able to compare probabilities
between men and women and discovered that men had significantly higher probabilities of
transition between the different stages of use. This finding confirms previous studies in an
American Indian population where men (0.57) were significantly more likely than women
(0.26) to transition from initiation of cannabis use to dependence (Ehlers et al., 2007). Data
from the National Comorbidity survey have also demonstrated that men had a higher risk of
developing cannabis dependence two years after initial use than women (Wagner & Anthony,
2007). Taken together these data suggest that cannabis may be more “addicting” to men than
women in the populations thus far evaluated.
In the UCSF Family Study there were no significant differences between men and women on
mean age of onset of cannabis use. However, survival analyses of the UCSF family population
revealed that those participants who began using cannabis at younger ages had significantly
different survival curves of use to dependence than those who began at a later age. These data
are consistent with a number of previous studies that have provided data to suggest that
individuals who use cannabis before the age of 15 years are substantially more likely to become
cannabis dependent (see Chen, O’Brien & Anthony, 2005; Ehlers et al., 2007; Wagner &
Anthony, 2002). The data from the UCSF study extends those findings and further suggests
that survival time for this population was significantly different based on gender with women
demonstrating an overall shorter survival time than men. One study of 156 women entering
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treatment for substance dependence reported that women experienced fewer years of regular
use of opioids and cannabis, and fewer years of regular alcohol drinking before entering
treatment (Hernandez-Avila, Rounsaville & Kranzler, 2004). These data are consistent with
several other studies that have reported “telescoping” (a more rapid progression from onset to
the development of clinical problems) of the clinical course of alcoholism in women (Diehl et
al., 2007; Ehlers et al., 2004; Randall et al., 1999). The present study may be the first to
demonstrate these phenomena in women for the transition between cannabis use and
dependence in a community sample.
The prevalence of cannabis dependence criteria have also been reported to differ between men
and women. Using data from the NESARC, Agrawal and Lynskey (2007) found that two
dependence criteria (quit and problems) showed significant gender heterogeneity and
suggested that criteria that serve as indicators of DSM-IV cannabis dependence may not
function identically in men and women. In the present study, within the population of
individuals who had used cannabis 21 or more time a year, more males endorsed “spending a
great deal of time obtaining, using, or recovering from” and “tolerance” to cannabis use.
Although no significant gender differences were found in any other of the cannabis dependence
criteria almost eighteen percent (17.8 %) of men and 15.6% of women in the UCSF study who
had used cannabis 21 or more time a year reported experiencing cannabis withdrawal. The
most common symptoms of withdrawal in the UCSF Family Study were “nervousness”,
“appetite change” and “trouble sleeping”. These three symptoms were also reported to be the
most common symptoms of cannabis withdrawal in the COGA study (Wiesbeck et al., 1996).
Grant et al. (2006) used latent class analyses to identify 4 classes of cannabis abuse and
dependence symptom patterns in data from the National Longitudinal Alcohol Epidemiology
Study (NLAES). They found that women in two of the classes were more likely to endorse
withdrawal. Lack of gender differences in the present study may be a result of a smaller sample
size than the NLAES. Several authors have provided data to suggest that cannabis withdrawal
is common in large epidemiological studies such as the NESARC, and that it should be
considered as a dependence criterion in DSM (see Agrawal et al., 2008a; Hasin et al., 2008).
4.2. Withdrawal and untoward side effects associated with cannabis use in the San Francisco
Family Study
Cannabis use has been associated with a number of untoward side effects. In youth under the
age of 20, marijuana was the most frequently reported drug in emergency department visits
(SAMHSA, 2006). A systematic review of safety studies of medical cannabinoids found that
short term use was associated with increased risk of adverse events and that risks associated
with long term use were “poorly characterized” (Wang, Collet, Shapiro & Ware, 2008). Using
a case control design, Gruber, Pope, Hudson, & Yurgelun-Todd, (2003) compared heavy
cannabis users to an age-matched control group and found that the users reported negative
effects of cannabis on their cognition, career, memory, social life as well as their physical and
mental health. Epidemiological studies suggest that cannabis use may be associated with
depression (see Degenhardt et al., 2003 for review) and psychosis (see Andreasson, Allebeck,
Engstrom & Rydberg, 1987; Henquet et al., 2005 for review). It is not possible at this time to
determine whether these associations are causal or due to common environmental factors that
increase the risks for both cannabis use and its untoward effects including symptoms of
depression and psychosis. In the UCSF study 29% of the sample reported depressive symptoms
17.9% hallucinations, 36.6% trouble concentrating, and 33% paranoia that lasted for more than
24 hours, confirming that cannabis use is associated with untoward side effects in this
population. Despite these untoward side effects, and the fact that 36% had wanted to quit using
the drug, very few participants had sought treatment for cannabis dependence in this
population. These data suggest that further efforts are needed to screen, identify and educate
cannabis users whose mental health may potentially benefit from abstinence.
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4.3. Heritability of cannabis use and symptomatology in the San Francisco Family Study
Cannabis use, cannabis dependence, the individual cannabis dependence criteria, and several
of the untoward side effects of cannabis use were all found to be significantly heritable in the
UCSF family population. These findings support previous studies in both female and male
twin pairs that have found resemblance and high heritability estimates for use and dependence
(Kendler & Prescott, 1998; Kendler et al., 2000); although, these studies generally have only
modest numbers of cannabis dependent participants. A review of the literature has reported
that cannabis use estimates of heritability ranged from 0.17 to 0.67 and estimates of heritability
of cannabis abuse or dependence at 0.45 to 0.78 (see Agrawal & Lynskey, 2006). In the UCSF
Family Study, estimates of the heritability of having tried and used more than 21 times in a
single year (0.52, 0.31), were similar to what has been reported in twin studies, but heritability
estimates of dependence (0.20) and age at first use (0.22) were somewhat lower.
How genetic and environmental factors may influence the age at which a person first tries
cannabis in such a way that it leads to increased risk for cannabis dependence has not been
completely formulated. One hypothesis posits that early substance use disrupts the normal
course of social and intellectual development leading to an increased risk for a number of social
and psychological pathologies including drug addictions (see De Wit, Adlaf, Offord &
Ofborne, 2000; York, 1999). An alternate hypothesis has been forwarded, suggesting that drug
addictions and psychopathology are in fact a reflection of a more general underlying
susceptibility to “addiction” through psychopathologies and disinhibitory behavior (see Heath
& Martin, 1988; Iacono, Carlson, Malone & McGue, 2002; McGue, Iacono, Legrand, Malone
& Elkins, 2001: Palmer et al., 2009; Prescott & Kendler, 1999; Room, Fischer, Hall, Lenton
& Reuter, 2008; Sartor et al., 2009). Although most studies point to age of onset of drug use
of as a primarily environmental variable it may represent different constructs at different ages.
For instance, very early onset of drug use (before the age of 13) may represent a more general
measure of disinhibitory behavior or conduct disorder and as such could potentially be more
heritable. In the present study, the number of individuals with very early onset of cannabis use
(<13 yrs) was limited and thus the statistical power for evaluation of the heritability of onset
of first cannabis use in this age group was limited. As adolescence progresses, cannabis use
becomes more common and may be highly influenced by such environmental variables such
as peer pressure and social circumstances; whereas, individuals who have not used cannabis,
the age of 21 may possess protective factors that may be both environmental (religion, family
norms) or genetic (intolerance of smoke). Early cannabis users appear to differ from their non
using peers in a variety of ways including: use of tobacco (Agrawal et al., 2008b), performing
poorly at school and having low academic expectations, having a problematic relationship with
parents, having a history of non conformist behavior and affiliating with drug using peers (see
Guxens, Nebot, Ariza & Ochoa, 2007; Hall & Degenhardt, 2007). Further studies are needed
to disentangle the environmental and heritable factors leading to onset of cannabis use in
adolescence.
The current findings suggest that within the UCSF Family Study population that genetic factors
highly influence whether an individual in this population may try or use cannabis but that
environmental factors may be more influential in determining whether a person becomes
dependent. The environmental factors that may influence cannabis dependence in this
population are not known but they may be related to the fact that this population was primarily
ascertained for alcohol dependence phenotypes. For instance, an individual with genetic risk
for cannabis and alcohol dependence may choose alcohol as a primary drug of abuse because
of availability or social acceptance of that drug use. Since the UCSF Family Study population
had a relatively high economic and education level these factors may also be protective in the
development of cannabis dependence among users. A recent study of data from male twins
from the Mid Atlantic Twin Registry demonstrated, using retrospective assessments of
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perceived cannabis availability between ages 8 and 25 years, that the latent shared
environmental factors responsible for cannabis initiation and abuse could be explained by a
measured aspect of the shared environment that had to do with variation in cannabis availability
(Gillespie, Neale & Kendler, 2009). Although drug availability was not measured in the San
Francisco Family Study our data certainly do not conflict with the hypothesis that shared
environmental variance in availability could explain much of the environmental risk for
cannabis dependence.
Several of the symptoms/criteria for DSM-IV cannabis dependence were also found to be
heritable in the UCSF family population. The highest heritabilities were found for “craving”
for and withdrawal from cannabis usage. These data suggest that these variables may be
preferred phenotypes for linkage analyses in this population. The findings that several of the
untoward side effects of cannabis use such as depression and paranoia were also in part heritable
further suggests that there may be a genetic component to the undesirable as well as the
desirable effects of cannabis, a finding that may be useful in designing treatment programs for
problematic cannabis users.
The results of this study should be interpreted in the context of several limitations. First, the
findings may not generalize to other samples of cannabis users that were ascertained without
bias. Second, only retrospective and cross-sectional data on cannabis use and use disorders
were assessed. Third, comparisons to other large samples may be limited by differences on a
variety of variables including recruitment, as well as a number of genetic and environmentally
determined variables. The exclusion criteria for this study eliminated participants reporting
serious drug dependence on stimulants, cocaine, or opiates, current diagnosis of schizophrenia,
bipolar disorder, or other psychiatric illness involving psychotic symptoms. This exclusion
was included to create a more homogeneous sample for genetic analyses. However, this
limitation reduces external validity and clinical applicability since the co-occurrence of mental
health disorders and substance abuse is common (Kessler et al., 1996). Finally, it should be
repeated that the family design cannot fully distinguish between additive genetic and shared
environmental influences, and this can lead to positively biased heritability estimates. The
inclusion of extended pedigrees containing relative pairs living apart provides some protection
against such bias, but is imperfect. Thus, replication of the reported heritability estimates should
represent an important priority for future studies.
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The following graphs exhibit the cumulative survival rates between two groups of subjects:
those who first used cannabis under age (13,15,17,19,21,25) group (♦) versus those whose first
used cannabis over age (13,15,17,19,21,25) group (◊) respectively. The cumulative survival
rate is the proportion of subjects within the group who survives (i.e. not developing cannabis
dependence) at different points in time after the subjects’ first exposure to cannabis. The
survival curves of the older cannabis consumption group (◊) are consistently above those of
the younger group (♦), and their survival curves diverge farther and farther apart as time
progresses. These graphs clearly indicate that subjects that use cannabis at a later age are more
likely to survive without cannabis dependence than those consume at an earlier age.
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Table 4
Psychiatric symptoms experienced as a consequence of cannabis use
Psychiatric Symptom n (%)
Decreased contact with family or friends 319 (40.2)
Trouble concentrating for > 24 hours 290 (36.6)
Paranoid/suspicious of people for > 24 hours 261 (32.8)
Depressed/uninterested in things for > 24 hours 231 (29.1)
Hallucinations 142 (17.9)
Withdrawal Symptom
Nervous, tense, restless or irritable 197 (24.2)
Appetite Change or Weight Change 165 (20.3)
Trouble sleeping 121 (14.9)
Trembling/Twitching 30 (3.7)
Sweating/Fever 24 (2.9)
Diarrhea/Stomach aches 17 (2.1)
Nausea/Vomiting 9 (1.1)













Ehlers et al. Page 22
Table 5
Heritability of Cannabis-Related Phenotypes
Trait Age (p) Sex (p) h2 p
Used cannabis <0.0001 0.52 <0.0001
Used ≥ 21 times year <0.0001 0.009 0.31 <0.0001
DSM-IV cannabis dependence <0.0001 0.048 0.20 <0.0001
Age at first use <0.0001 <0.0001 0.22 0.002
DSM-IV Symptoms
Emotional/psychological problems <0.0001 0.131 0.23 <0.0001
Cannabis avoid withdrawal <0.0001 0.014 0.25 0.0001
Cannabis reduced activities <0.0001 0.21 <0.0001
Great deal of time using <0.0001 0.002 0.29 <0.0001
Multiple withdrawal symptoms <0.0001 0.043 0.26 <0.0001
Tried stop cannabis <0.0001 0.249 0.23 <0.0001
Want stop cannabis <0.0001 0.007 0.15 0.002
Tolerance <0.0001 0.637 0.25 <0.0001
Used more than intended <0.0001 0.11 0.01
Cannabis Consequences
Cannabis depressed > a day <0.0001 0.03 0.16 0.0006
Cannabis concentrating > a day <0.0001 0.19 <0.0001
Cannabis paranoid > a day <0.0001 0.11 0.008
Cannabis “craving” <0.0001 0.36 <0.0001
Cannabis nervous during withdrawal <0.0001 0.28 0.30 <0.0001
Cannabis hallucinations > a day <0.0001 0.07 0.07
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